Maviret is a combination of the following two DAAs:
glecaprevir – a protease inhibitor that works by interfering with a protein needed by the virus
pibrentasvir – an NS5A (hepatitis C virus non-structural protein 5A) inhibitor that interferes with the production of the pieces needed to build new virus particles
Together, these two drugs greatly reduce and then stop the production of new copies of HCV.
MAVIRET (GLECAPREVIR/PIBRENTASVIR) INDICATIONS:
Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and in adolescents aged 12 to <18 years